SCHEDULE 13D

CUSIP No.

20454B104

1

Name of reporting person

Commander Aggregator, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,788,150.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,788,150.00

11

Aggregate amount beneficially owned by each reporting person

7,788,150.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Percentage of ownership is based upon 171,572,498 shares of common stock, par value $0.0001 per share ("Common Stock"), issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) ("Prospectus") with the Securities and Exchange Commission ("SEC") on August 13, 2025.

SCHEDULE 13D

CUSIP No.

20454B104

1

Name of reporting person

Enavate Sciences, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,788,150.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,788,150.00

11

Aggregate amount beneficially owned by each reporting person

7,788,150.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

CUSIP No.

20454B104

1

Name of reporting person

Enavate Sciences GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,788,150.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,788,150.00

11

Aggregate amount beneficially owned by each reporting person

7,788,150.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

CUSIP No.

20454B104

1

Name of reporting person

Enavate Sciences Holdings, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,788,150.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,788,150.00

11

Aggregate amount beneficially owned by each reporting person

7,788,150.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, par value $0.0001 per share

(b)

Name of Issuer:

Compass Therapeutics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

80 Guest St., Suite 601, Boston, MASSACHUSETTS , 02135.

Item 1 Comment:

This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends and supplements the initial Schedule 13D filed on November 14, 2022 (as so amended, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D as amended from time to time.

Item 5.

Interest in Securities of the Issuer

(a)

Item 5(a) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

(b)

Item 5(b) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

(c)

None of the Reporting Entities has effected any transactions in the Common Stock in the past 60 days.

(d)

Not Applicable

(e)

As a result of the decrease in the outstanding shares, effective as of August 14, 2025, as reported by the Issuer in the Prospectus filed on August 13, 2025, the Reporting Entities' beneficial ownership ceased to exceed 5% on such date and the Reporting Entities are no longer subject to Section 13 reporting.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commander Aggregator, LP

Signature:	/s/ James P. Boylan
Name/Title:	James P. Boylan / Chief Executive Officer
Date:	08/18/2025

Enavate Sciences, LP

Signature:	/s/ James P. Boylan
Name/Title:	James P. Boylan / Chief Executive Officer
Date:	08/18/2025

Enavate Sciences GP, LLC

Signature:	/s/ James P. Boylan
Name/Title:	James P. Boylan / Chief Executive Officer
Date:	08/18/2025

Enavate Sciences Holdings, LLC

Signature:	/s/ James P. Boylan
Name/Title:	James P. Boylan / Chief Executive Officer
Date:	08/18/2025

Comments accompanying signature:

Enavate Sciences, LP By: Enavate Sciences GP, LLC Its: General Partner, Enavate Sciences GP, LLC By: Enavate Sciences Holdings, LLC Its: Sole Member